Universal influenza vaccines: a realistic option?

Vries, Rory D. de; Altenburg, Arwen F.; Rimmelzwaan, Guus F.

doi:10.1016/j.cmi.2015.12.005

Cited by 16 publications

(14 citation statements)

References 77 publications

(86 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite seasonal vaccination, influenza virus infection remains associated with high morbidity and mortality rates (Simonsen, 1999). This is due to continuous antigenic changes in the surface glycoproteins of influenza virus strains, which reduce the effectiveness of vaccination (de Vries et al, 2016;Webster and Govorkova, 2014). Antiviral drugs can be used to treat patients with severe influenza virus infection.…”

Section: Introductionmentioning

confidence: 99%

Development and evaluation of a rapid nucleic acid amplification method to detect influenza A and B viruses in human respiratory specimens

Elf

Auvinen

Jahn

et al. 2018

Diagnostic Microbiology and Infectious Disease

View full text Add to dashboard Cite

Isothermal nucleic acid amplification methods can potentially shorten the amount of time required to diagnose influenza. We developed and evaluated a novel isothermal nucleic acid amplification method, RT-SIBA to rapidly detect and differentiate between influenza A and B viruses in a single reaction tube. The performance of the RT-SIBA Influenza assay was compared with two established RT-PCR methods. The sensitivities of the RT-SIBA, RealStar RT-PCR, and CDC RT-PCR assays for the detection of influenza A and B viruses in the clinical specimens were 98.8%, 100%, and 89.3%, respectively. All three assays demonstrated a specificity of 100%. The average time to positive result was significantly shorter with the RT-SIBA Influenza assay (<20 min) than with the two RT-PCR assays (>90 min). The method can be run using battery-operated, portable devices with a small footprint and therefore has potential applications in both laboratory and near-patient settings.

show abstract

Section: Introductionmentioning

confidence: 99%

Development and evaluation of a rapid nucleic acid amplification method to detect influenza A and B viruses in human respiratory specimens

Elf

Auvinen

Jahn

et al. 2018

Diagnostic Microbiology and Infectious Disease

View full text Add to dashboard Cite

show abstract

“…These cells are induced by natural infection but are induced V C 2017 British Society for Immunology, Clinical and Experimental Immunology, 190: [19][20][21][22][23][24][25][26][27][28] inefficiently by inactivated influenza vaccines (reviewed in [11]) [12][13][14]. These cells are induced by natural infection but are induced V C 2017 British Society for Immunology, Clinical and Experimental Immunology, 190: [19][20][21][22][23][24][25][26][27][28] inefficiently by inactivated influenza vaccines (reviewed in [11]) [12][13][14].…”

Section: Introductionmentioning

confidence: 99%

“…It has been shown that cross-reactive virusspecific CD8 1 cytotoxic T cells contribute to reduction of disease duration and severity after infection with a heterologous influenza virus [12,15]. Thus, the development of vaccines that induce broadly protective HA stalk-specific antibodies and/or cellular immune responses against conserved proteins such as NP or M1 is highly desirable and is listed high on the research agenda (reviewed in [21][22][23]). Thus, the development of vaccines that induce broadly protective HA stalk-specific antibodies and/or cellular immune responses against conserved proteins such as NP or M1 is highly desirable and is listed high on the research agenda (reviewed in [21][22][23]).…”

Section: Introductionmentioning

confidence: 99%

Protein and modified vaccinia virus Ankara-based influenza virus nucleoprotein vaccines are differentially immunogenic in BALB/c mice

Altenburg

Magnusson

Bosman

et al. 2017

Clinical and Experimental Immunology

View full text Add to dashboard Cite

Because of the high variability of seasonal influenza viruses and the eminent threat of influenza viruses with pandemic potential, there is great interest in the development of vaccines that induce broadly protective immunity. Most probably, broadly protective influenza vaccines are based on conserved proteins, such as nucleoprotein (NP). NP is a vaccine target of interest as it has been shown to induce cross-reactive antibody and T cell responses. Here we tested and compared various NP-based vaccine preparations for their capacity to induce humoral and cellular immune responses to influenza virus NP. The immunogenicity of protein-based vaccine preparations with Matrix-M™ adjuvant as well as recombinant viral vaccine vector modified Vaccinia virus Ankara (MVA) expressing the influenza virus NP gene, with or without modifications that aim at optimization of CD8 T cell responses, was addressed in BALB/c mice. Addition of Matrix-M™ adjuvant to NP wild-type protein-based vaccines significantly improved T cell responses. Furthermore, recombinant MVA expressing the influenza virus NP induced strong antibody and CD8 T cell responses, which could not be improved further by modifications of NP to increase antigen processing and presentation.

show abstract

“…However, the 'stalk' supporting the binding site is relatively well conserved. 3,4 "Recent advances in understanding how to preserve the structure of the stem antigen in the vaccine suggests that a universal vaccine for flu is a realistic prospect," says Dr Drury. "All being well, a candidate vaccine could be available in 10 to 15 years.…”

Section: Mark Greenermentioning

confidence: 99%